INVESTOR LOGIN

Entire SVLSF Portfolio Current SVLSF Investments Exited SVLSF Investments SVLSFV SVLSF IV SVLSF III SVLSF II SVLSF I IBT

Exited SVLSF investments

Please see below a list of our exited investments

To go to individual portfolio companies websites please click on company logo.

SV Life Sciences Fund I (SVLSFI)

Allos Therapeutics: US - Exited

First investment: 1998 - Early Stage

Allos Therapeutics was developing and commercializing innovative small molecule therapeutics for the treatment of cancer.

Axys Pharmaceuticals: US - Exited

First investment: 1994 - Early Stage

Axys developed a protease-inhibitor based products for cancer & inflammatory diseases.

Cerebrus: UK - Exited

First investment: 1995 - Start Up

Cerebrus CNS drug discovery (Acquired by Nigra, which was then bought by Vernalis)

Coral Therapeutics: US - Exited

First investment: 1994 - Start Up

Coral was a provision of blood handling services to hospitals.

Cytomed: US - Exited

First investment: 1997 - Early Stage

Cytomed was a leukotriene inhibitors for asthma (Acquired by LeukoSite Inc and then by Millenium).

Euro Dentalversand: Germany - Exited

First investment: 2000 - Buyout

Euro was mail order dental consumables.

Geltex Pharmaceuticals: US - Exited

First investment: 1995 - Early Stage
Further investment: 1998 - Expansion

Geltex developed novel non-absorbed pharmaceuticals.

Geltex was acquired by Genzyme Corporation after our exit.

General Surgical Innovations: US - Exited

First investment: 1995 - Early Stage

General Surgical Innovations is a minimally invasive approach to hernia repair and incontinence (purchased by United States Surgical).

Genosis: UK - Exited

First investment: 1999 - Start Up

Genosis has developed home use diagnostic devices to assess fertility in couples of
childbearing age. Genosis’ products - Fertell, which provide both male and female tests, are
available over the counter in the UK and the US and provide couples with the tools required to
assess their fertility in the privacy of their homes.

Heritage Health Systems: US - Exited

First investment: 1995 - Early Stage

Heritage was a physician practice.

Incyte Pharmaceuticals: UK - Exited

First investment: 1996 - Start Up

Functional genomics (Acquired by Incyte).

JC Nationwide: US - Exited

First investment: 1995 - Buyout

JC Nationwide was a physician recruitment agency.

Kinetix Pharmaceuticals: US - Exited

First investment: 1999 - Start Up

Kinase targeted drug discovery (Acquired by Amgen).

Leica Microsystems: Germany - Exited

First investment: 1998 - Buyout

Leica Manufactured and marketed microscopes and neurosurgical equipment.

LeukoSite: US - Exited

First investment: 1994 - Start Up

LeukoSite was a treatment of Inflammatory diseases and cancer (Acquired by Millenium).

MedNova: Ireland - Exited

First investment: 1996 - Start Up

MedNova was a device for interventional radiology and cardiology.

Metris Therapeutics: UK - Exited

First investment SVLSF I: 1998 - Start Up
First investment SVLSF II: 2000 - Start Up

Metris is a women’s healthcare company that is developing drugs for the treatment of chronic gynecological and menstrual conditions.

Micromass: UK - Exited

First investment: 1996 - Buyout

Micromass was a minimally invasive approach to hernia repair and incontinence (purchased by Waters).

MicroMed: US - Exited

First investment: 1998 - Early Stage

MicroMed based in Houston, TX, has developed an implantable pump for use as a Left Ventricular Assist Device (LVAD) to aid the heart’s pumping action in patients suffering from
congestive heart failure.

Nexan: UK - Exited

First investment: 1996 - Start Up

Nexan was a remote telemonitoring devices.

OMS Foundations: US - Exited

First investment: 1998 - Early Stage

OMS Foundations was an oral maxillofacial physician practice management.

Orthovita: US - Exited

First investment: 1997 - Early Stage

Orthovita was a novel bone substitute materials company.

Pelton & Crane: US - Exited

First investment: 1997 - Buyout

Pelton & Crane developed sterilization equipment.

Shire Pharmaceuticals: US - Exited

First investment: 1994 - Early Stage

Shire Pharmaceuticals - osteoporosis and Alzheimer's disease.

Sirona Dental Systems: Germany - Exited

First investment: 1997 - Buyout

Sirona was a dental equipment manufacturer.

Strides Arcolab: India - Exited

First investment: 1997 - Expansion

Strides Arcolab was a manufacturer of generic pharmaceuticals.

TLC Vision: US - Exited

First investment: 1995 - Expansion

TLC Vision was a service provider for laser-based ophthalmic surgery. Formerly known as Laservision.

Triangle Pharmaceuticals: US - Exited

First investment: 1995 - Start Up

Triangle Pharmaceuticals was an antiviral and anticancer drug development company (Acquired by Gilead).

Vanguard Medica (Vernalis): UK - Exited

First investment: 1995 - Early Stage

Vanguard Medica was an antiviral and anticancer drug development company. (Acquired by Vernalis)

Vintage BioMed: US - Exited

First investment: 1996 - Seed

Vintage BioMed was a capital equipment leasing and maintenance company.

SV Life Sciences Fund II (SVLSFII)

Aderis Pharmaceuticals: US - Exited

First investment: 2001 - Expansion

Aderis Pharmaceuticals was a Cardiovascular, renal and neurological disease focused therapeutics focused upon making a significant difference to people living with cardiovascular, renal and neurological diseases.

Affibody: Sweden - Exited

First investment: 2001 - Early Stage

Affibody is a biotech company that uses unique affinity ligands to develop products for molecular imaging, targeted therapy and biotechnology applications. The lead product is a Her2 affibody for clinical imaging in breast cancer, and its pipeline includes other oncology imaging affibodies. In addition, affibodies are sold as research reagents and for use in protein separations.

Argonaut Technologies: US - Exited

First investment: 1999 - Expansion

Argonaut developed a chemistry instrumentation for accelerated synthesis of novel organic molecules. Bought by Biotage after our exit.

Auxilium Pharmaceuticals: US - Exited

First investment: 2001 - Early Stage

Auxilium developed a male hormone replacement therapy.

Cardiac Support Systems: US - Exited

First investment: 2000 - Seed

Cardiac Support Systems was an innovation factory company.

Celldex/Lorantis: UK - Exited

First investment SVLSF II: 2000 - Start Up
First investment SVLSF III: 2003 - Early Stage

Celldex merged with the quoted company Avant Immunotherapeutics (ticker:'AVAN') in March 2008. Celldex, formerly a wholly owned subsidiary of Medarex Inc., merged with Lorantis Ltd in 2005. Celldex pursues immunological approaches to the treatment of cancers, infectious disease and immunological disorders.

Cerebral Vascular Applications: US - Exited

First investment: 2000 - Seed

Cerebral Vascular Applications incubated by TIF) developed a set of minimally invasive tools for atrial appendage sealing for stroke prevention. Licensed to Epitek.

Funded through the innovation factory

Confluent Surgical: US - Exited

First investment: 1999 - Early Stage

Confluent Surgical was a biomaterials for adhesion prevention and vascular embolics.

EasyChem: US - Exited

First investment: 2000 - Seed

EasyChem was a B2B chemical e-commerce electronic marketplace.

eMed Technologies: US - Exited

First investment: 2000 - Expansion

eMed Delivered medical images over the internet.

Expand Sante: France - Exited

First investment: 2000 - Seed

Expand Sante was a French pharmaceutical contract sales organisation.

Eyetech Pharmaceuticals: US - Exited

First investment: 2000 - Early Stage

Eyetech was bought by OSI Pharmaceuticals after our exit. Opthalmolological drug development.

IHG Holdings: US - Exited

First investment: 2001 - Buyout

IHG was a preferred provider organization. (Formerly known as Interplan).

Ingenium: Germany - Exited

First investment: 2000 - Early Stage

Ingenium was a functional genomics and drug development company.

Insulet: US - Exited

First investment SVLSF II: 2001 - Start Up

Insulet based in Bedford, MA, Insulet is designing and developing products that provide superior treatment for people with diabetes. The Company’s first commercial product is a wireless 3-day insulin pump.

KuDOS Pharmaceuticals: UK - Exited

First investment: 1999 - Start Up

KuDOS was an oncology drug development company.

LipoSonix: US - Exited

First investment SVLSF II: 2001 - Seed
First investment SVLSF III: 2003 - Seed

LipoSonix based in Bothell, WA, was developing a product to use non-invasive, high intensity focused ultrasound to ablate unwanted subcutaneous cells as a non-invasive alternative to liposuction for body sculpting.

Funded through the innovation factory.

Mdeverywhere: US - Exited

First investment: 2001 - Early Stage

Mdeverywhere based in Hauppauge, NY with operations in New Dehli, India, is an outsourced physician billing company.

Orchid Chemicals and Pharmaceuticals: India - Exited

Private investment in Public Equity
First investment: 1999 - Expansion

Orchid manufactured bulk generic pharmaceuticals.

Phase Forward: US - Exited

First investment: 1999 - Expansion

Phase Forward was a web-based information technology for clinical trials management.

Physicians Dialysis: US - Exited

First investment: 2001 - Buyout

Physicians Dialysis was a consolidator of renal dialysis centers (Purchased by DaVita).

Quantum Dot: US - Exited

First investment: 2000 - Early Stage

Quantum Dot developed nanocrystal biological reagents.

Solexa: UK - Exited

First investment: 2001 - Start Up

Solexa used ultra high throughput DNA sequencing.

Third Wave Technologies: US - Exited

First investment: 1999 - Expansion

Third Wave developed products for analysing genetic variations.

Trine Pharmaceuticals: US - Exited

First investment: 2001 - Expansion

Trine, formerly Essential Therapeutics Inc., in-licenses, develops and plans to commercialize new classes of pharmaceutical products focused on renal, metabolic and GI clinical areas.

Versicor: US - Exited

First investment: 1999 - Expansion

Versicor was a drug development company for infectious diseases (Changed name to Vicurion Pharmaceuticals in 2003)

SV Life Sciences Fund III (SVLSFIII)

Alantos Pharmaceuticals: US - Exited

First investment: 2003 - Early Stage

Alantos was a chemistry-driven company seeking to discover and develop drugs targeted at osteoarthritis and inflammatory processes. The company attempts to fast follow others to reduce risk.

Allegiance Hospice Group: US - Exited

First investment: 2005 - Start Up

Allegiance Hospice is based in Lowell, MA, focused on providing hospice services to patients primarily in long- term care facilities within the New England market.

Avera Pharmaceuticals: US - Exited

First investment: 2004 - Early Stage

Avera is based in San Diego, CA and focused on the development of small molecule drugs for the treatment of diseases affecting the central nervous system (CNS). Key programs are Alzheimer’s disease, schizophrenia associated cognition deficits, IBS, and OAB, and developing an ultra-short acting anaesthesia compound.

Celldex/Lorantis: UK - Exited

First investment SVLSF II: 2001 - Seed
First investment SVLSF III: 2003 - Seed

Celldex merged with the quoted company Avant Immunotherapeutics (ticker:'AVAN') in March 2008. Celldex, formerly a wholly owned subsidiary of Medarex Inc., merged with Lorantis Ltd in 2005. Celldex pursues immunological approaches to the treatment of cancers, infectious disease and immunological disorders.

Cellutions: US - Exited

First investment: 2004 - Seed

Cellutions is based in Duluth, GA, (TIF)is developing a minimally invasive approach for addressing cellulite and its appearance on the skin.

Dynogen Pharmaceuticals: US - Exited

First investment: 2004 - Early Stage

Dynogen is a neuroscience-based company focused on genito-urinary (GU) and gastro-intestinal (GI) disorders. The company is using its knowledge of neurology and GU/GI disorders to build a pipeline of clinical candidates.

Eunoe: US - Exited

First investment: 2003 - Expansion

Eunoe was a treatment of neurological disorders through cerebrospinal fluid management (CSF).

GlycoFi: US - Exited

First investment: 2002 - Start Up

GlycoFi was a production and engineering of therapeutics proteins.

Gyros: Sweden - Exited

First investment: 2002 - Start Up

Gyros, located in Uppsala, Sweden, has developed a proprietary microfluidics technology for processing and analysis of proteins and blood samples. Laboratory processes are integrated into a client specific disc (CD) format. The CD is processed and its contents analysed on software controlled instrumentation.

Insulet: US - Exited

First investment SVLSF III: 2004 - Late Stage

Insulet based in Bedford, MA, Insulet is designing and developing products that provide superior treatment for people with diabetes. The Company’s first commercial product is a wireless 3-day insulin pump.

Patient Care: US - Exited

First investment: 2002 - Buyout

Patient Care based in Orange, NJ, is one of the largest independent home health agencies.

PowderMed: UK - Exited

First investment: 2004 - Early Stage

PowderMed developed therapeutic DNA vaccines in the areas of chronic viral diseases and cancer.

Rinat Neuroscience: US - Exited

First investment: 2003 - Early Stage

Rinat developed proteins for the treatment of diseases and disorders of the nervous system.

Sapphire Pharmaceuticals: US - Exited

First investment: 2004 - Early Stage

Helsinn is developing small molecule drugs based on the biology of ghrelin,a gut peptide known to stimulate appetite. The lead compound is in Ph II for cancer cachexia; a second compound has completed an initial clinical study and is moving toward Ph II for post-operative ileus. Additional indications are being explored for follow-on compounds.

Formerly known as Rejuvenon.

Synarc: US - Exited

First investment: 2004 - Late Stage

Synarc provides centralized medical imaging services and international subject-recruitment facilities dedicated exclusively to global clinical trials.

SV Life Sciences Fund IV (SVLSFIV)

RespiVert: UK - Exited

First Investment: 2007 - Start Up

RespiVert is a discovery company focused on Chronic obstructive pulmonary disease ('COPD') and severe asthma. The company’s goal is to develop novel inhaled and intranasal drugs for respiratory disorders with high unmet medical need and high commercial potential based on novel insights on biology and chemistry.

X2-Pharma: Germany - Exited

First investment: 2008 - Seed

X2-Pharma is a biopharmaceutical company dedicated to the discovery and development of small molecule pharmaceuticals for the treatment of inflammatory diseases.

web design - xenex-media.com